Mesothelioma malignant – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:09 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Mesothelioma malignant – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Tulmimetostat (CPI-0209) for Patients with Advanced Solid Tumors and Lymphomas https://clinicaltrials.eu/trial/study-of-tulmimetostat-cpi-0209-for-patients-with-advanced-solid-tumors-and-lymphomas/ Wed, 29 Apr 2026 14:30:12 +0000 https://clinicaltrials.eu/trial/study-of-tulmimetostat-cpi-0209-for-patients-with-advanced-solid-tumors-and-lymphomas/ This clinical trial is focused on studying the effects of a new treatment called CPI-0209 in patients with advanced forms of cancer. The types of cancer being studied include various solid tumors and lymphomas. Solid tumors are abnormal masses of tissue that usually do not contain cysts or liquid areas, while lymphomas are cancers that begin in the cells of the immune system. Some specific cancers included in this study are urothelial carcinoma, ovarian clear cell cancer, endometrial carcinoma, malignant pleural or peritoneal mesothelioma, and metastatic castration-resistant prostate cancer (mCRPC). The treatment being tested, CPI-0209, is taken orally in the form of a film-coated tablet and contains the active substance tulmimetostat.

The purpose of this study is to determine the best dose of CPI-0209 and to evaluate its effectiveness in treating these advanced cancers. The study is divided into two phases. In the first phase, researchers aim to find the maximum dose that patients can tolerate. In the second phase, the focus is on assessing how well CPI-0209 works in shrinking or controlling the tumors. Patients participating in the study will receive either CPI-0209 or a placebo, and their health will be monitored closely throughout the trial.

Participants in the study will undergo regular health assessments, including blood tests and imaging scans, to track the progress of their treatment. The study will help researchers understand the potential benefits and side effects of CPI-0209, contributing to the development of new treatment options for patients with these challenging types of cancer. The trial is expected to continue until 2025, providing valuable insights into the treatment of advanced solid tumors and lymphomas.

]]> Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials https://clinicaltrials.eu/trial/56496/ Wed, 29 Apr 2026 14:29:10 +0000 https://clinicaltrials.eu/trial/56496/ This study focuses on evaluating a medication called tazemetostat, which is given as a film-coated tablet taken by mouth. The study aims to assess the long-term safety of this medication in patients who have previously been treated with tazemetostat in other clinical trials and have shown benefit from the treatment.

The study will monitor patients who continue taking tazemetostat either alone or in combination with other approved or experimental medications. During the study, researchers will track any side effects that may occur and how well patients tolerate the medication over an extended period. The medication will be provided according to each patient’s previous treatment plan.

Participants will be monitored for various health measures, including their blood cell counts, kidney function, and liver function. The study will also track how long patients survive while receiving the treatment. This is an open-label study, which means all participants will receive the active medication, and there is no use of a placebo.

]]>